Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium.

cardiovascular diseases (CVDs) clinical algorithm coronavirus disease 2019 (COVID-19) diabetes healthcare services obesity personal protective equipment (PPE)

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2020
Historique:
received: 16 04 2020
accepted: 01 06 2020
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 3 7 2020
Statut: epublish

Résumé

Patients with cardiovascular disease and diabetes are at potentially higher risk of infection and fatality due to COVID-19. Given the social and economic costs associated with disability due to these conditions, it is imperative that specific considerations for clinical management of these patients be observed. Moreover, the reorganization of health services around the pandemic response further exacerbates the growing crisis around limited access, treatment compliance, acute medical needs, and mental health of patients in this specific subgroup. Existing recommendations and guidelines emanating from respective bodies have addressed some of the pressure points; however, there are variations and limitations

Identifiants

DOI: 10.3389/fcvm.2020.00112 PMID: 32613010 PMC: PMC7308556
pubmed: 32613010
doi: 10.3389/fcvm.2020.00112
pmc: PMC7308556
doi:

Types de publication

Journal Article

Langues

eng

Pagination

112

Informations de copyright

Copyright © 2020 Bhaskar, Rastogi, Chattu, Adisesh, Thomas, Alvarado, Riahi, Varun, Pai, Barsam and Walker.

Références

Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4
pubmed: 15671045
Lancet Diabetes Endocrinol. 2020 Jun;8(6):474-475
pubmed: 32359411
Europace. 2017 Aug 1;19(8):1280-1287
pubmed: 27738071
Life Sci. 2006 Feb 28;78(14):1535-42
pubmed: 16229862
Eur Heart J. 2020 May 14;41(19):1791-1794
pubmed: 32232396
Hypertension. 2004 May;43(5):970-6
pubmed: 15007027
Int J Ment Health Addict. 2020 Mar 27;:1-9
pubmed: 32226353
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
JAMA. 2020 Feb 24;:
pubmed: 32091533
Infection. 2020 Apr 28;:
pubmed: 32342479
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927
Mayo Clin Proc. 2020 Jun;95(6):1213-1221
pubmed: 32359771
Circulation. 2020 Apr 14;:
pubmed: 32286863
Clin Infect Dis. 2020 Apr 09;:
pubmed: 32271368
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thromb Haemost. 2010 Nov;8(11):2450-7
pubmed: 20738765
Allergy. 2020 Feb 19;:
pubmed: 32077115
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2019 Sep 20;10:2249
pubmed: 31616424
Diabetes Care. 2016 Nov;39(11):2065-2079
pubmed: 27926890
JAMA Cardiol. 2019 Feb 1;4(2):163-173
pubmed: 30649175
Lancet. 2020 Apr 11;395(10231):1194
pubmed: 32246915
J Diabetes Investig. 2018 Jul;9(4):946-951
pubmed: 29095573
BMJ. 2020 Mar 24;368:m1201
pubmed: 32209544
JAMA. 2020 Feb 7;:
pubmed: 32031570
Clin Sci (Lond). 2012 Dec;123(11):649-58
pubmed: 22715807
Lancet Respir Med. 2020 May;8(5):440-442
pubmed: 32247325
World J Diabetes. 2015 Oct 10;6(13):1246-58
pubmed: 26468341
Lancet Diabetes Endocrinol. 2020 Jul;8(7):562-564
pubmed: 32437642
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):124-135
pubmed: 29698642
J Cell Mol Med. 2015 Aug;19(8):1965-74
pubmed: 25766467
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Lab Invest. 2000 May;80(5):617-53
pubmed: 10830774
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Lancet Haematol. 2020 May;7(5):e362-e363
pubmed: 32278361
N Engl J Med. 2020 Apr 29;:
pubmed: 32348640
Nat Med. 2020 Jun;26(6):808-809
pubmed: 32488217

Auteurs

Sonu Bhaskar (S)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Liverpool Hospital & South West Sydney Local Health District (SWSLHD), Department of Neurology & Neurophysiology, Sydney, NSW, Australia.
Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, NSW, Australia.
NSW Brain Clot Bank, NSW Health Statewide Biobank, Sydney, NSW, Australia.
South Western Sydney Clinical School, University of New South Wales (UNSW), Sydney, NSW, Australia.

Aarushi Rastogi (A)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, NSW, Australia.
South Western Sydney Clinical School, University of New South Wales (UNSW), Sydney, NSW, Australia.

Vijay Kumar Chattu (VK)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Anil Adisesh (A)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Pravin Thomas (P)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Negman Alvarado (N)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Neurophysiology, Instituto Médico Dr. Rodriguez Alfici, Godoy Cruz, Argentina.

Anis D Riahi (AD)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Neurology, Faculty of Medicine, Military Hospital of Tunis, University of Tunis El Manar, Tunis, Tunisia.

Chakrakodi N Varun (CN)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
State Level Virus Research and Diagnostics Laboratory, Bangalore Medical College and Research Institute, Bengaluru, India.

Anupama R Pai (AR)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Neuromicrobiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.

Sarah Barsam (S)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Hematology, North Middlesex Hospital, King's Thrombosis Center & King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom.

Antony H Walker (AH)

Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, CVD and Metabolic REPROGRAM Sub-committee†, Sydney, NSW, Australia.
Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, NHS, Blackpool, United Kingdom.

Classifications MeSH